Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
HMGB1P13 is a human pseudogene annotated as “high mobility group box 1 pseudogene 13.” It is an inactive genetic element related to the HMGB1 protein family and does not encode a functional protein or participate in molecular signaling, transcription regulation, or therapeutic targeting. Unlike the HMGB1 protein—which is a well-studied DNA-binding protein with diverse roles in chromatin structure, transcription, and inflammation—HMGB1P13 does not have established biological functions, pharmacology, or disease relevance[5]. Pseudogenes often share sequence similarity with their parent genes but lack the ability to encode active proteins due to genetic mutations or disruptions. HMGB1P13 has no verified protein product or receptor activity and thus is not considered a therapeutic target or a molecular target for drug discovery[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on High mobility group box 1 pseudogene 13 (HMGB1P13).